Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

15

Revenue 2017

Neulasta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Neulasta was produced by Amgen.

FDA accepts Sandoz filing for biosimilar Neulasta

FDA accepts Sandoz filing for biosimilar Neulasta Neulasta (pegfilgrastim) is a long-acting granulocyte colony stimulating factor (G-CSF) that is used to bolster white cells in patients undergoing chemotherapy for cancer, and remains one of Amgen's ... The patents on Neulasta expired in the US in

Roche maintains top place in biologic sales

Roche maintains top place in biologic sales Novo Nordisk and Sanofi see large sales from their insulin products while Amgen's bone drug Prolia (denosumab) and chemotherapy side effects drug Neulasta(pegfilgrastim), make up the bulk of its

Amgen starts shipping Corlaner in US

Amgen starts shipping Corlaner in US Top seller Neulasta (pegfilgrastim) climbed 4% to $1.13bn, with the greatest growth coming from Prolia (denosumab) for osteoporosis - up 39% to $272m - and recently-introduced multiple myeloma therapy Kyprolis (carfilzomib) ... Launches this year already

Apotex latest to file Neupogen biosimilar in the US

Apotex latest to file Neupogen biosimilar in the US Meanwhile, biosimilar competition is also looming for Amgen's long-acting version of Neupogen, Neulasta(pegfilgrastim), which is due to lose US patent protection in October of this year.

Amgen banking on three launches in 2015

Amgen banking on three launches in 2015 Long-acting white blood cell stimulator Neulasta (pegfilgrastim) grew 7% to $1.1bn, although its short-acting predecessor Neupogen (filgrastim) slumped 11% thanks to competition from biosimilars. ... Bradway also highlighted the approval of a new on-body

[ Previous 5 results ] 1 2 3 4 5 6 7 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Research Partnership

Research Partnership is now a member of Inizio Advisory, the consulting business unit of Inizio, a strategic partner for health...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...